Want to see GB:SCLP full AI Analyst Report?
Top Page
Scancell Holdings
(LSE:SCLP)
Select Model
Select Model
Rating:53Neutral
Price Target:
24.00 p
▲(155.32% Upside)
Action:Reiterated
Date:05/21/26
The score is capped primarily by weak financial strength (continued losses, cash burn, and negative equity) and valuation constraints from negative earnings. This is partially offset by strong earnings-call-driven clinical/regulatory momentum and a clear Phase III path, while technicals show an uptrend but also very overbought conditions that elevate short-term volatility risk.
Positive Factors
Compelling Phase II efficacy signal
A strong PFS signal from Phase II materially raises the probability of clinical success and partner interest. Over the medium term this supports a credible registrational strategy, strengthens negotiating leverage for licensing/milestones and de-risks development compared with programs lacking such translational evidence.
Negative Factors
Negative shareholder equity
Persistently negative equity and modest asset base constrain financial flexibility and make leverage ratios less meaningful. Over months this weak capital structure amplifies refinancing risk, limits ability to fund expensive Phase III activities internally and increases dependency on partner deals or dilutive financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Compelling Phase II efficacy signal
A strong PFS signal from Phase II materially raises the probability of clinical success and partner interest. Over the medium term this supports a credible registrational strategy, strengthens negotiating leverage for licensing/milestones and de-risks development compared with programs lacking such translational evidence.
Read all positive factors
Scancell Holdings (SCLP) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£116.37M
Dividend YieldN/A
Average Volume (3M)1.20M
Price to Earnings (P/E)―
Beta (1Y)-0.11
Revenue GrowthN/A
EPS Growth69.01%
CountryUK
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,212,230,700
10 Day Avg. Volume991,653
30 Day Avg. Volume1,200,950
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)-27.20
Price to Sales (P/S)22.14
P/FCF Ratio-17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)£1.20M
Scancell Holdings Business Overview & Revenue Model
Company Description
Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. Th...
How the Company Makes Money
Scancell’s business model is typical of an R&D-stage biotechnology company: it seeks to create value by advancing proprietary immunotherapy candidates through preclinical and clinical development and then monetizing those assets via partnerships a...
Scancell Holdings Earnings Call Summary
Earnings Call Date:Jan 29, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 23, 2026
Earnings Call Sentiment Positive
The call conveyed strong clinical and regulatory progress—most notably the FDA IND clearance, compelling PFS data (74% at 16 months with a 24% delta), validated manufacturing and delivery, and multiple pipeline and partnered value drivers (including up to $630M in Genmab milestones). The primary negatives are financial (no revenue, interim net loss, and a cash runway into H2 2026) and the long, blinded Phase III timeline to a registrational readout in H2 2029 which necessitates near-term financing or milestone receipts. On balance, the positive clinical/regulatory milestones and clear commercial pathway outweigh the funding and timing headwinds.Positive Updates
Strong Efficacy Signal for iSCIB1+ (PFS)
iSCIB1+ demonstrated progression-free survival (PFS) of 74% at 16 months in Phase II data; reported a 24% delta versus historic/real-world benchmarks (comparison with ipilimumab+nivolumab median PFS ~11.5 months). Company also reported a ~16% improvement for prior SCIB1 on overall survival versus the comparator in their dataset, and noted similarity in order of magnitude to published Moderna 5‑year follow-up data.
Negative Updates
No Revenues Reported in Period
There were no revenues in the interim period; revenue upside depends on future partnered milestones (Genmab) and commercial success.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Efficacy Signal for iSCIB1+ (PFS)
iSCIB1+ demonstrated progression-free survival (PFS) of 74% at 16 months in Phase II data; reported a 24% delta versus historic/real-world benchmarks (comparison with ipilimumab+nivolumab median PFS ~11.5 months). Company also reported a ~16% improvement for prior SCIB1 on overall survival versus the comparator in their dataset, and noted similarity in order of magnitude to published Moderna 5‑year follow-up data.
Read all positive updates
Company Guidance
Management guided that iSCIB1+—which showed 74% PFS at 16 months (a ~24 percentage‑point delta versus historic ipi/nivo data with median PFS ≈11.5 months) from a Phase II translational dataset of ~140 patients—will move to a registrational Phase III two‑arm study of ~230 patients per arm (~460 total) with an adaptive design, IND cleared by the FDA, a surrogate primary endpoint (enabling accelerated approval), plans to pursue Fast Track and a Breakthrough designation (decision timeline ~2–3 months) and a target readout/commercialization window in H2 2029; financially, H1 (6 months to 31 Oct 2025) R&D spend was $6.2m, admin costs £2.7m, operating loss £8.9m, net loss £5.7m, cash £8.6m (including a £3.0m R&D tax credit) giving runway into H2 2026, while management pursues partnering/financing (including up to $630m of potential Genmab milestones), expects Modi‑1 data in H1, anticipates further Genmab/SC129 milestones this year, and notes patent protection to 2041 plus scalable manufacturing and a PharmaJet needle‑free delivery partnership.Scancell Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Apr 2025 | Apr 2024 | Oct 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.71M | 4.71M | 0.00 | 5.27M | 0.00 | 0.00 |
| Gross Profit | 3.70M | 3.59M | -966.00K | 4.75M | -740.00K | -249.00K |
| EBITDA | -5.60M | -12.71M | -7.06M | -12.19M | -3.75M | -14.90M |
| Net Income | -5.51M | -12.27M | -5.86M | -11.94M | -2.06M | -15.48M |
Balance Sheet | ||||||
| Total Assets | 15.38M | 23.09M | 23.58M | 30.27M | 49.06M | 8.82M |
| Cash, Cash Equivalents and Short-Term Investments | 8.57M | 16.89M | 14.82M | 19.92M | 28.73M | 41.11M |
| Total Debt | 16.18M | 16.27M | 19.87M | 21.13M | 18.92M | 15.39M |
| Total Liabilities | 23.75M | 26.93M | 27.08M | 36.50M | 29.57M | 1.17M |
| Stockholders Equity | -8.37M | -3.83M | -3.50M | -6.23M | 18.11M | 19.48M |
Cash Flow | ||||||
| Free Cash Flow | -8.36M | -6.12M | -15.84M | -8.34M | -8.55M | -4.80M |
| Operating Cash Flow | -8.35M | -6.11M | -15.66M | -8.14M | -7.80M | -4.77M |
| Investing Cash Flow | -1.44M | -1.54M | 178.00K | 81.00K | -741.00K | -13.00K |
| Financing Cash Flow | 9.22M | 9.73M | 10.39M | -746.00K | 46.08M | 46.08M |
Scancell Holdings Technical Analysis
Negative
9.40
Price Trends
14.57
Negative
15.62
Negative
13.51
Negative
Market Momentum
-1.38
Negative
25.09
Positive
31.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SCLP, the sentiment is Negative. The current price of 9.4 is below the 20-day moving average (MA) of 10.25, below the 50-day MA of 14.57, and below the 200-day MA of 13.51, indicating a bearish trend. The MACD of -1.38 indicates Negative momentum. The RSI at 25.09 is Positive, neither overbought nor oversold. The STOCH value of 31.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SCLP.
Scancell Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | £64.89M | -9.14 | -55.47% | ― | ― | 19.83% | |
53 Neutral | £116.37M | -18.11 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £71.28M | -4.04 | -1411.54% | ― | 22.87% | 13.35% | |
47 Neutral | £36.92M | -7.28 | -284.01% | ― | ― | -105.65% | |
46 Neutral | £22.47M | 33.81 | 14.26% | ― | ― | ― | |
43 Neutral | £85.17M | -5.05 | -116.21% | ― | 81.46% | -15.88% |
* Healthcare Sector Average
GB:SCLP
Scancell Holdings
9.54
-0.96
-9.14%
GB:SAR
Sareum Holdings
28.00
5.00
21.74%
GB:4BB
4basebio UK Societas
492.00
-398.00
-44.72%
GB:POLB
Poolbeg Pharma Ltd.
8.70
5.70
190.00%
GB:AREC
Arecor Therapeutics PLC
61.00
-2.50
-3.94%
GB:OBI
Ondine Biomedical, Inc.
12.10
-5.90
-32.78%
Scancell Holdings Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
Scancell Raises £15.7m After Oversubscribed Retail Offer and UK Placing
Positive
Jul 27, 2026
Scancell Holdings has confirmed that its retail offer, conducted via the Winterflood Retail Access Platform, was significantly oversubscribed and ultimately raised gross proceeds of £2.7 million at 9 pence per share, with allocations scaled b...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Scancell and Neuphoria in all-share merger backed by $89m financing for melanoma trial
Positive
Jul 24, 2026
Scancell Holdings and U.S.-based Neuphoria Therapeutics have agreed an all-share merger that will create a combined company operating under the Scancell name, with Scancell shareholders owning about 85.5% and Neuphoria investors 14.5%. The merged ...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and Financing
Scancell upsizes oversubscribed £13m UK placing to extend funding runway
Positive
Jul 23, 2026
Scancell Holdings has upsized its UK equity placing, raising £13.0 million through the issue of 144,444,444 new shares, equivalent to about 13.9% of its existing share capital, after strong investor demand significantly oversubscribed the ori...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Scancell launches discounted UK share placing to fund Phase 3 melanoma trial
Neutral
Jul 23, 2026
Scancell Holdings plans to raise about $12 million (£9 million) through a non-pre-emptive UK placing of new ordinary shares at 9 pence, a 29.4% discount to the previous close, targeting new and existing institutional investors. Alongside this...
Business Operations and StrategyPrivate Placements and Financing
Scancell launches retail offer and placing to extend cash runway into 2027
Neutral
Jul 23, 2026
Scancell Holdings has launched a retail offer via the Winterflood Retail Access Platform to raise up to £2.3 million through the issue of around 25 million new shares at 9 pence each, alongside a previously announced UK placing targeting abou...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingStock Split
Scancell to Merge with Neuphoria and Secure Up to $89m for Phase 3 Melanoma Trial
Positive
Jul 23, 2026
Scancell Holdings and Neuphoria Therapeutics have agreed an all-share merger that will create a combined immuno-oncology company operating under the Scancell name and listed on both AIM and Nasdaq. Existing Scancell shareholders are expected to ow...
Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
Scancell in advanced talks on Neuphoria reverse merger and Nasdaq listing
Positive
Jun 26, 2026
Scancell Holdings has confirmed it is in advanced talks with U.S.-listed Neuphoria Therapeutics over a potential all-share reverse merger that would see Scancell acquire the neuropsychiatry-focused biotech and secure a Nasdaq listing. The move is ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.